SCHEMBL318775

SCHEMBL318775

Nc1cnccc1C1OCCO1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC1 P19801 2/20 0.38
AOC3 Q16853 2/20 0.38
GAA P10253 2/20 0.36
NSD2 O96028 1/20 0.36
CASP6 P55212 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM6B O15054 1/20 0.36
KDM4A O75164 1/20 0.36
THRB P10828 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GLA P06280 1/20 0.33
LMNA P02545 2/20 0.32
CYP2D6 P10635 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320625 0.93 AOC1 (0.36) AOC1AOC3GAANSD2CASP6
SCHEMBL319430 0.78 AOC1 (0.33) AOC1AOC3GAAKDM4EALDH1A1
SCHEMBL16703948 0.77 AXL (0.32) AXLRPS6KA3
SCHEMBL29939336 0.74 RPS6KA3 (0.50) AOC1AOC3GAAKDM4EALDH1A1
SCHEMBL16702989 0.74 RPS6KA3 (0.50) AOC1AOC3GAAKDM4EALDH1A1
SCHEMBL319870 0.74 AOC3 (0.33) AOC1AOC3GAAKDM4EALDH1A1
SCHEMBL19849321 0.74 AOC3 (0.33) AOC1AOC3GAAKDM4EALDH1A1
SCHEMBL1911019 0.74 AOC3 (0.33) AOC1AOC3GAAKDM4EALDH1A1
SCHEMBL793757 0.74 AOC1 (0.42) AOC1AOC3GAAKDM4EALDH1A1
SCHEMBL29517316 0.74 AOC1 (0.42) AOC1AOC3GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626885-A1 CYCLOBUTYL SUBSTITUTED BICYCLIC COMPOUNDS Janssen Pharmaceutica NV (BE) 2025-10-08 EP disclosed
WO-2024114662-A1 CYCLOBUTYL SUBSTITUTED BICYCLIC COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2024-06-06 WO disclosed
EP-2590968-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS Novartis AG (CH) 2013-05-15 EP disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS PIM1, GSK3A, GSK3B AOC1 4470/4885AOC3 4852/4885GAA 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.